Comparative Pharmacology
Head-to-head clinical analysis: RAPLON versus SERPIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAPLON versus SERPIVITE.
RAPLON vs SERPIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RAPLON (levosimendan) is a calcium sensitizer that increases myocardial contractility by sensitizing troponin C to calcium, and it also opens ATP-sensitive potassium channels, causing vasodilation.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
0.2 mg/kg IV bolus over 30 seconds; may repeat once if necessary after 15 minutes.
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours in end-stage renal disease).
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (approximately 80-90% of administered dose within 24 hours); minor biliary/fecal elimination (less than 10%).
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Category C
Category C
Antihypertensive
Antihypertensive